Назаров Константин Сергеевич (RU),Лыткин Роман Викторович (RU),Кадагидзе Эраст Бессарионович (RU),Ульянов Алексей Сергеевич (RU)
申请号：
RU2013155974/15
公开号：
RU2013155974A
申请日:
2013.12.17
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. Use of a chitosan wherein the chitosan moiety has the general formula (I) wherein R - amino acid residue or a fatty, n for the hydrophilic ligand is from about 12 to about 25% relative to the amount of monosaccharide residues chitosan, m hydrophobic ligand is from about 30 to about 60% relative to the amount of monosaccharide residues chitosan for the manufacture of a medicament or biologically active kompleksa.2. Use according to claim 1, characterized in that the medicament is for delivery to selective organizm.3. Use according to claim 2, characterized in that the medicament is intended for the selective delivery into the body cheloveka.4. Use according to claim 1, characterized in that the active compound complex for selective delivery to organizm.5. Use according to claim 4, characterized in that the active compound complex for selective delivery to the body cheloveka.6. Use according to claim 1, characterized in that said fatty acid residue is a residue of caprylic kisloty.7. Use according to claim 1, characterized in that said amino acid residue is a residue valina.8. Use according to claim 1, characterized in that said derivative nanostrukturirovano.9. Use according to claim 1, characterized in that said derivative is a transdermal and / or membrane pronitsaemost.10. Use according to claim 1, characterized in that the said derivative has improved sorptive emkost.11. Use according to claim 1, characterized in that said derivative is soluble at a pH of about 2 to about 9, preferably from about 4 to about 9, more n1. Применение производного хитозана, в котором хитозановый фрагмент имеет общую формулу (I)гдеR - остаток жирной или аминокислоты,n для гидрофильного лиганда составляет от около 12 до около 25% относительно количества моносахаридных остатков хитозана,m для гидрофобного лиганда составляет от около 30 до около 60% относительно количества моносахаридных остатков хитозана,для изготовления лекарственного средства или биологически активного комплекса.2.
